Genzyme Corp. and Bone Care International Inc. won a U.S. judge’s ruling that their patent for the kidney disease drug Hectorol is valid and enforceable.
Merck & Co.’s blockbuster cholesterol drug Vytorin won the backing of an advisory panel to prevent heart attack and stroke in some patients with kidney disease.
An experimental drug from Abbott Laboratories and Reata Pharmaceuticals Inc. reversed the decline of kidney function in diabetics in a study that doctors say may lead to a new way of treating chronic kidney disease.
Merck & Co., the second-biggest U.S. drugmaker, said cholesterol treatments Vytorin and Zetia failed to win approval to prevent heart attacks and strokes in patients with chronic kidney disease.
Opko’s Frost Discusses Treatment of Kidney Disease (Audio)
Taking Stock: Manley on Markets, Frost on Biotech (Audio)